PLK Inhibitors Come of Age in Pediatric Brain Tumors

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2022 Jan 11

PMID 35015893

Authors

Shinji Maegawa

Vidya Gopalakrishnan

Affiliations

Soon will be listed here.

Citing Articles

Pin1 as a central node in oncogenic signaling: Mechanistic insights and clinical prospects (Review).

Lei S, Luo M, Wang Y Mol Med Rep. 2025; 31(3).

PMID: 39886975 PMC: 11795255. DOI: 10.3892/mmr.2025.13445.

Identification of 3-Aryl-1-benzotriazole-1-yl-acrylonitrile as a Microtubule-Targeting Agent (MTA) in Solid Tumors.

Zoroddu S, Sanna L, Bordoni V, Weidong L, Gadau S, Carta A Int J Mol Sci. 2024; 25(11).

PMID: 38891892 PMC: 11172098. DOI: 10.3390/ijms25115704.

References

Wang D, Veo B, Pierce A, Fosmire S, Madhavan K, Balakrishnan I . A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy. Neuro Oncol. 2021; 24(3):414-426. PMC: 8917408. DOI: 10.1093/neuonc/noab207. View

Pajovic S, Siddaway R, Bridge T, Sheth J, Rakopoulos P, Kim B . Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer. Nat Commun. 2020; 11(1):6216. PMC: 7718276. DOI: 10.1038/s41467-020-19972-7. View

Northcott P, Korshunov A, Witt H, Hielscher T, Eberhart C, Mack S . Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2010; 29(11):1408-14. PMC: 4874239. DOI: 10.1200/JCO.2009.27.4324. View

Leary S, Olson J . The molecular classification of medulloblastoma: driving the next generation clinical trials. Curr Opin Pediatr. 2011; 24(1):33-9. PMC: 3348176. DOI: 10.1097/MOP.0b013e32834ec106. View

Ramaswamy V, Remke M, Adamski J, Bartels U, Tabori U, Wang X . Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?. Neuro Oncol. 2015; 18(2):291-7. PMC: 4724171. DOI: 10.1093/neuonc/nou357. View

Schmidt C, Schubert N, Brabetz S, Mack N, Schwalm B, Chan J . Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. Neuro Oncol. 2017; 19(12):1607-1617. PMC: 5716199. DOI: 10.1093/neuonc/nox093. View

Xiao D, Yue M, Su H, Ren P, Jiang J, Li F . Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival. Mol Cell. 2016; 64(3):493-506. DOI: 10.1016/j.molcel.2016.09.016. View

Ellis P, Leighl N, Hirsh V, Reaume M, Blais N, Wierzbicki R . A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015; 16(6):457-65. DOI: 10.1016/j.cllc.2015.05.010. View

Zeidan A, Ridinger M, Lin T, Becker P, Schiller G, Patel P . A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2020; 26(23):6132-6140. DOI: 10.1158/1078-0432.CCR-20-2586. View

10.

Gutteridge R, Ndiaye M, Liu X, Ahmad N . Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics. Mol Cancer Ther. 2016; 15(7):1427-35. PMC: 4936921. DOI: 10.1158/1535-7163.MCT-15-0897. View